1. Home
  2. GF vs TLSA Comparison

GF vs TLSA Comparison

Compare GF & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GF

New Germany Fund Inc. (The)

HOLD

Current Price

$11.94

Market Cap

184.9M

Sector

Finance

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.52

Market Cap

192.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GF
TLSA
Founded
1990
2013
Country
Germany
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.9M
192.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GF
TLSA
Price
$11.94
$1.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.7K
130.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.80
$0.73
52 Week High
$12.82
$2.60

Technical Indicators

Market Signals
Indicator
GF
TLSA
Relative Strength Index (RSI) 45.49 55.64
Support Level $11.74 $1.29
Resistance Level $12.06 $1.65
Average True Range (ATR) 0.18 0.10
MACD -0.04 0.02
Stochastic Oscillator 12.85 86.11

Price Performance

Historical Comparison
GF
TLSA

About GF New Germany Fund Inc. (The)

NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: